Literature DB >> 16086213

When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant?

Isao Miyashiro1, Ko Takachi, Yuichiro Doki, Osamu Ishikawa, Hiroaki Ohigashi, Kohei Murata, Yo Sasaki, Shingi Imaoka, Akihiko Nakaizumi, Akemi Takenaka, Hiroshi Furukawa, Masahiro Hiratsuka.   

Abstract

For gastric cancer patients who have no peritoneal seeding at a macroscopic level but positive results in the peritoneal lavage cytology (PLC), the prognostic benefit expected by surgical resection is still controversial. During the period 1975-1994 as series of 417 consecutive patients without distant organ metastases underwent surgical resection for gastric cancer that had invaded the subserosal or deeper layers of the stomach wall. Immediately after laparotomy, the pouch of Douglas was washed with 100 ml of physiologic saline solution, and the fluid was collected for cytologic examination (four slide glasses) using Giemsa and Papanicolaou staining methods. According to the macroscopic (P) and cytologic (Cyt) results, the 417 patients were classified into three groups: P(+) (n = 97); P(-)/Cyt(+) (n = 25); and P(-)/Cyt(-) (n = 295). Their 3-year survival rates after surgical resection were 4%, 24%, and 48%, respectively (p = 0.0001: P(-)/Cyt(+) vs. P(-)/Cyt(-); p = 0.0018: P(-)/Cyt(+) vs. P(+). Among the 25 P(-)/Cyt(+) patients, postoperative survival was not associated with the T stage, N stage, cellular atypism, or cluster formation but with the number of cancer cells per slide during PLC. The 3-year survival rate was 35% for the subgroup with fewer than 10 cancer cells per slide (17 patients) and 0% for the other subgroup with 10 or more cancer cells per slide (8 patients) (p = 0.017). For P(-)/Cyt(+) patients, who represent a subgroup of gastric cancer patients with an intermediate survival rate between the P(-)/Cyt(-) and P(+) patients, the number of cancer cells observed during PLC offers a potent prognostic indicator for the gastrectomy.

Entities:  

Mesh:

Year:  2005        PMID: 16086213     DOI: 10.1007/s00268-005-7703-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  16 in total

1.  Prognostic significance of the cytologic features of free cancer cells in the peritoneal cavity of patients with gastric cancer.

Authors:  Takashi Majima; Takashi Ichikura; Hidetaka Mochizuki
Journal:  Surg Today       Date:  2002       Impact factor: 2.549

2.  Prognostic and therapeutic values of peritoneal cytology in gastric cancer.

Authors:  T Nakajima; S Harashima; M Hirata; T Kajitani
Journal:  Acta Cytol       Date:  1978 Jul-Aug       Impact factor: 2.319

3.  [Important prognostic factors in surgically treated gastric cancer patients].

Authors:  M Hiratsuka; T Iwanaga; H Furukawa; T Yasuda; H Nakano; S Nakamori; H Ohigashi; M Kameyama; Y Sasaki; T Kabuto
Journal:  Gan To Kagaku Ryoho       Date:  1995-04

4.  Viability of intraperitoneal free cancer cells in patients with gastric cancer.

Authors:  O Tanida; S Kaneshima; Y Iitsuka; H Kuda; Y Kiyasu; S Koga
Journal:  Acta Cytol       Date:  1982 Sep-Oct       Impact factor: 2.319

5.  Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy.

Authors:  L L Gunderson; H Sosin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-01       Impact factor: 7.038

6.  Japanese Classification of Gastric Carcinoma - 2nd English Edition -

Authors: 
Journal:  Gastric Cancer       Date:  1998-12       Impact factor: 7.370

7.  Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma.

Authors:  E Bando; Y Yonemura; Y Takeshita; K Taniguchi; T Yasui; Y Yoshimitsu; S Fushida; T Fujimura; G Nishimura; K Miwa
Journal:  Am J Surg       Date:  1999-09       Impact factor: 2.565

8.  Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.

Authors:  M Markman; M F Brady; N M Spirtos; P Hanjani; S C Rubin
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

9.  Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer.

Authors:  T Boku; Y Nakane; T Minoura; H Takada; M Yamamura; K Hioki; M Yamamoto
Journal:  Br J Surg       Date:  1990-04       Impact factor: 6.939

10.  Peritoneal cytology in the surgical evaluation of gastric carcinoma.

Authors:  N Hayes; J Wayman; V Wadehra; D J Scott; S A Raimes; S M Griffin
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  20 in total

1.  The current role of staging laparoscopy in oesophagogastric cancer.

Authors:  L Convie; R J Thompson; R Kennedy; W D B Clements; P D Carey; J A Kennedy
Journal:  Ann R Coll Surg Engl       Date:  2015-03       Impact factor: 1.891

2.  Significance of lavage cytology in advanced gastric cancer patients.

Authors:  Takeo Fukagawa; Hitoshi Katai; Makoto Saka; Shinji Morita; Yuko Sasajima; Hirokazu Taniguchi; Takeshi Sano; Mitsuru Sasako
Journal:  World J Surg       Date:  2010-03       Impact factor: 3.352

3.  Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy.

Authors:  Itaru Yasufuku; Souya Nunobe; Satoshi Ida; Koshi Kumagai; Manabu Ohashi; Naoki Hiki; Takeshi Sano
Journal:  Gastric Cancer       Date:  2019-07-26       Impact factor: 7.370

4.  Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer.

Authors:  Seiji Satoh; Hiroshi Okabe; Satoshi Teramukai; Suguru Hasegawa; Nobuhiro Ozaki; Shugo Ueda; Ayumi Tsuji; Satomi Sakabayashi; Masanori Fukushima; Yoshiharu Sakai
Journal:  Gastric Cancer       Date:  2011-06-11       Impact factor: 7.370

5.  Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy.

Authors:  Chakrapan Euanorasetr; Panuwat Lertsithichai
Journal:  Gastric Cancer       Date:  2007-02-23       Impact factor: 7.370

6.  Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2.

Authors:  Isao Miyashiro; Hiroshi Furukawa; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Toshifusa Nakajima; Taira Kinoshita; Osamu Kobayashi; Kuniyoshi Arai
Journal:  Gastric Cancer       Date:  2011-02-19       Impact factor: 7.370

Review 7.  Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients.

Authors:  Shunsuke Kagawa; Kunitoshi Shigeyasu; Michihiro Ishida; Megumi Watanabe; Hiroshi Tazawa; Takeshi Nagasaka; Yasuhiro Shirakawa; Toshiyoshi Fujiwara
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

8.  Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients.

Authors:  Zhen Li; Dewei Zhang; Hao Zhang; Zhifeng Miao; Yuanxin Tang; Gongping Sun; Dongqiu Dai
Journal:  Tumour Biol       Date:  2013-11-27

9.  Feasibility of laparoscopic gastrectomy for advanced gastric cancer with positive peritoneal cytology.

Authors:  Naoki Yamanaka; Eishi Nagai; Kenoki Ohuchida; Junji Ueda; Hiroki Toma; Shuji Shimizu; Yasunori Oda; Masao Tanaka
Journal:  Surg Today       Date:  2012-09-16       Impact factor: 2.549

10.  High postoperative neutrophil-lymphocyte ratio and low preoperative lymphocyte-monocyte ratio predict poor prognosis in gastric cancer patients receiving gastrectomy with positive lavage cytology: a retrospective cohort study.

Authors:  Sho Sato; Chikara Kunisaki; Masazumi Takahashi; Hirokazu Kubo; Nobuhiro Tsuchiya; Kei Sato; Hiroshi Miyamoto; Yuko Tamura; Hiroki Kondo; Yusaku Tanaka; Kohei Kasahara; Takashi Kosaka; Hirotoshi Akiyama; Yusuke Saigusa; Itaru Endo
Journal:  Langenbecks Arch Surg       Date:  2021-06-17       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.